

Catalog Number: CM01915

## 产品信息

**Catalog Number:**  
CM01915

**CAS号:**  
1416992-39-6


**分子式:**  
 $C_{21}H_{30}N_3NaO_8S$

**主要靶点:**  
SARS-CoV

**主要通路:**  
微生物学

**分子量:**  
507.53

**溶解度:**  
5% DMSO+95% Saline:2.25  
mg/mL (4.43 mM);DMSO:45  
mg/mL (88.66 mM)



## 靶点活性

3CLpro:0.49-4.35  $\mu$  M.

## 体外活性

GC376对冠状病毒 (TGEV、FIPV、MHV、229E和BCV)、卡利西病毒 (NV和MNV-1) 以及皮克纳病毒 (HRVs 18、51和68、EV71和PTV) 表现出显著的抑制效果, IC50值达到纳摩尔或低微摩尔水平, 除了FCV和HAV外。有趣的是, FCV对GC376的敏感性较低, 其IC50值为35  $\mu$  M [1]。

## 体内活性

GC376以15 mg/kg的剂量, 每12小时通过皮下注射给药。结果表明, 在初始治疗后的2周内, 20只接受GC376治疗的猫中有19只恢复了正常健康状况。然而, 疾病迹象在初次治疗后1-7周内复发, 复发和新发病例最终需要至少治疗12周。在初次或重复治疗后的1-7周内, 13只中的19只猫发生了不再对治疗有反应的复发 [2]。

## 动物实验

GC376 was synthesized in a highly pure form and formulated at a concentration of 53 mg/ml in 10% ethanol and 90% polyethylene glycol 400, as described previously. GC376 was administered subcutaneously (SC) at a dosage of 15 mg/kg q12h SC, unless stated otherwise. The effective dosage for cats with experimentally induced FIP was 10 mg/kg/ q12h SC, but the dosage was raised to 15 mg/kg after the first cat (CT01) failed to respond to a lower dose of 10 mg/kg suggested by earlier pharmacokinetic studies. This was a clinical decision based on this one cat's response to treatment [2].

## 细胞实验

The toxic dose for 50% cell death (TD50) for each compound was determined for the various cells used in this study. Confluent cells grown in 96-well plates were treated with various concentrations (1 to 500  $\mu$  M) of each compound for 72 h. Cell cytotoxicity was measured by a CytoTox 96 nonradioactive cytotoxicity assay kit and crystal violet staining. The in vitro therapeutic index was calculated by dividing the TD50 by the IC50 [1].

## 储存

Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.